IQGAP1 is an oncogenic target in canine melanoma.
Canine oral mucosal melanoma is an aggressive malignant neoplasm and is characterized by local infiltration and a high metastatic potential. The disease progression is similar to that of human oral melanomas. Whereas human cutaneous melanoma is primarily driven by activating mutations in Braf (60%)...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2017-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC5406000?pdf=render |
| _version_ | 1811320417246248960 |
|---|---|
| author | Becky H Lee Poornima H Neela Michael S Kent Ashley M Zehnder |
| author_facet | Becky H Lee Poornima H Neela Michael S Kent Ashley M Zehnder |
| author_sort | Becky H Lee |
| collection | DOAJ |
| description | Canine oral mucosal melanoma is an aggressive malignant neoplasm and is characterized by local infiltration and a high metastatic potential. The disease progression is similar to that of human oral melanomas. Whereas human cutaneous melanoma is primarily driven by activating mutations in Braf (60%) or Nras (20%), human mucosal melanoma harbors these mutations much less frequently. This makes therapeutic targeting and research modeling of the oral form potentially different from that of the cutaneous form in humans. Similarly, research has found only rare Nras mutations and no activating Braf mutations in canine oral melanomas, but they are still reliant on MAPK signaling. IQGAP1 is a signaling scaffold that regulates oncogenic ERK1/2 MAPK signaling in human Ras- and Raf- driven cancers, including melanomas. To investigate whether IQGAP1 is a potential target in canine melanoma, we examined the expression and localization of IQGAP1 in primary canine melanomas and canine oral melanoma cell lines obtained from the University of California-Davis. Using CRISPR/Cas9 knockout of IQGAP1, we examined effects on downstream ERK1/2 pathway activity and assayed proliferation of cell lines when treated with a peptide that blocks the interaction between IQGAP1 and ERK1/2. We observed that canine IQGAP1 is expressed and localizes to a similar extent in both human and canine melanoma by qPCR, Western blot, and immunofluorescence. Deletion of IQGAP1 reduces MAPK pathway activation in cell lines, similar to effects seen in human BrafV600E cell lines. Additionally, we demonstrated reduced proliferation when these cells are treated with a blocking peptide in vitro. |
| first_indexed | 2024-04-13T12:59:11Z |
| format | Article |
| id | doaj.art-0fdac7b691af4101aa4355e271a38b38 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-13T12:59:11Z |
| publishDate | 2017-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-0fdac7b691af4101aa4355e271a38b382022-12-22T02:45:58ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01124e017637010.1371/journal.pone.0176370IQGAP1 is an oncogenic target in canine melanoma.Becky H LeePoornima H NeelaMichael S KentAshley M ZehnderCanine oral mucosal melanoma is an aggressive malignant neoplasm and is characterized by local infiltration and a high metastatic potential. The disease progression is similar to that of human oral melanomas. Whereas human cutaneous melanoma is primarily driven by activating mutations in Braf (60%) or Nras (20%), human mucosal melanoma harbors these mutations much less frequently. This makes therapeutic targeting and research modeling of the oral form potentially different from that of the cutaneous form in humans. Similarly, research has found only rare Nras mutations and no activating Braf mutations in canine oral melanomas, but they are still reliant on MAPK signaling. IQGAP1 is a signaling scaffold that regulates oncogenic ERK1/2 MAPK signaling in human Ras- and Raf- driven cancers, including melanomas. To investigate whether IQGAP1 is a potential target in canine melanoma, we examined the expression and localization of IQGAP1 in primary canine melanomas and canine oral melanoma cell lines obtained from the University of California-Davis. Using CRISPR/Cas9 knockout of IQGAP1, we examined effects on downstream ERK1/2 pathway activity and assayed proliferation of cell lines when treated with a peptide that blocks the interaction between IQGAP1 and ERK1/2. We observed that canine IQGAP1 is expressed and localizes to a similar extent in both human and canine melanoma by qPCR, Western blot, and immunofluorescence. Deletion of IQGAP1 reduces MAPK pathway activation in cell lines, similar to effects seen in human BrafV600E cell lines. Additionally, we demonstrated reduced proliferation when these cells are treated with a blocking peptide in vitro.http://europepmc.org/articles/PMC5406000?pdf=render |
| spellingShingle | Becky H Lee Poornima H Neela Michael S Kent Ashley M Zehnder IQGAP1 is an oncogenic target in canine melanoma. PLoS ONE |
| title | IQGAP1 is an oncogenic target in canine melanoma. |
| title_full | IQGAP1 is an oncogenic target in canine melanoma. |
| title_fullStr | IQGAP1 is an oncogenic target in canine melanoma. |
| title_full_unstemmed | IQGAP1 is an oncogenic target in canine melanoma. |
| title_short | IQGAP1 is an oncogenic target in canine melanoma. |
| title_sort | iqgap1 is an oncogenic target in canine melanoma |
| url | http://europepmc.org/articles/PMC5406000?pdf=render |
| work_keys_str_mv | AT beckyhlee iqgap1isanoncogenictargetincaninemelanoma AT poornimahneela iqgap1isanoncogenictargetincaninemelanoma AT michaelskent iqgap1isanoncogenictargetincaninemelanoma AT ashleymzehnder iqgap1isanoncogenictargetincaninemelanoma |